Ruixia Zhao, Sinan Cheng, Xue Bai, Danying Zhang, Hongming Fang, Wanlin Che, Wenxuan Zhang, Yujuan Zhou, Wei Duan, Qiumin Liang, Li Xiao, Guochao Nie, Yingchun Hou
Hepatocellular carcinoma (HCC) is a digestive tract cancer with high mortality and poor prognosis, especially in China. Current chemotherapeutic drugs lead to poor prognosis, low efficacy, and high side effects due to weak targeting specificity and rapidly formed multidrug resistance (MDR). Based on the previous studies on the doxorubicin (DOX) formulation for cancer targeting therapy, we developed a novel DOX delivery formulation for the targeting chemotherapy of HCC and DOX resistant HCC. HCSP4 was previously screened and casein kinase 2α (CK2α) was predicted as its specific target on HCC cells in our lab...
April 2024: Biotechnology Journal